Form D · Biotechnology
RELMADA THERAPEUTICS, INC.
New York, NY · CIK 0001553643
Offering snapshot reported Oct 8, 2019 · SEC filing
- Reported sold
- $826K Offering amount: $826K
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Sep 23, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 8, 2019 | Initial | $825,750 | No comparison | 7 | SEC filing |
| Jul 10, 2019 | Amendment | $8,432,437 | $430,189vs Jun 27, 2019 | 116 | SEC filing |
| Jun 27, 2019 | Initial | $8,002,248 | No comparison | 108 | SEC filing |
| May 16, 2019 | Initial | $3,414,505 | No comparison | 43 | SEC filing |
| Dec 10, 2018 | Amendment | $5,834,407 | $2,554,409vs Oct 22, 2018 | 66 | SEC filing |
| Nov 13, 2018 | Amendment | $4,629,507 | $1,349,509vs Oct 22, 2018 | 55 | SEC filing |
| Oct 22, 2018 | Initial | $3,279,998 | No comparison | 30 | SEC filing |
| Oct 6, 2017 | Initial | $6,890,000 | No comparison | 65 | SEC filing |
| Jun 19, 2014 | Initial | $10,694,588 | No comparison | 236 | SEC filing |
| Jun 4, 2014 | Initial | $0 | No comparison | 382 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-350641
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| None | None |
Source: Form D, filed Oct 8, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Shreeram Agharkar | Director |
| Douglas Beck | Executive |
| Charles Casamento | Director |
| Chuck Ence | Executive |
| Paul Kelly | Director |
| Eliseo O. Salinas | Executive |
| Sandesh Seth | Director |
| Maged Shenouda | Director |
| Sergio Traversa | Director, Executive |
| Ottavio Vitolo | Executive |
| Nabil M. Yazgi | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
880 3 Rd Avenue, 12 Th Floor
New York, NY, 10022
New York, NY, 10022